Grace Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed Jun 18, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2026 · Filed Jun 18, 2026
GRCE$1.87+0.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 11. Executive Compensation
The information required by this Item will be set forth under the sections entitled “Executive Compensation” and “Director Compensation” in our 2026 Proxy Statement to be filed with the SEC within 120 days of March 31, 2026 and is incorporated by reference into this Annual Report on Form 10-K.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.